🇺🇸 FDA
Patent

US 9217024

ADDL receptor polypeptides, polynucleotides and host cells for recombinant production

granted A61PA61P25/00A61P25/28

Quick answer

US patent 9217024 (ADDL receptor polypeptides, polynucleotides and host cells for recombinant production) held by Acumen Pharmaceuticals, Inc. expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Acumen Pharmaceuticals, Inc.
Grant date
Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P25/00, A61P25/28